Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Silvia Schenone

Showing results (31-40 of 173) with videos related to

Pageof 18
Sort By:
Pharmaceuticals (Basel, Switzerland)|May 25, 2024
Recent Advances in the Discovery of SIRT1/2 Inhibitors via Computational Methods: A PerspectiveNaomi Scarano, Chiara Brullo, Francesca Musumeci, et al.
Plos One|December 15, 2010
Molecular characterization of c-Abl/c-Src kinase inhibitors targeted against murine tumour progenitor cells that express stem cell markersThomas Kruewel, Silvia Schenone, Marco Radi, et al.
Bioorganic & Medicinal Chemistry|November 3, 2005
Affinity prediction on A1 adenosine receptor agonists: the chemometric approachPaola Fossa, Luisa Mosti, Francesco Bondavalli, et al.
European Journal of Medicinal Chemistry|May 20, 2025
Approaching Gallium-68 radiopharmaceuticals for tumor diagnosis: a Medicinal Chemist's perspectiveFrancesca Musumeci, Alessandro Fasce, Marta Falesiedi, et al.
European Journal of Medicinal Chemistry|May 5, 2009
Determination of permeability and lipophilicity of pyrazolo-pyrimidine tyrosine kinase inhibitors and correlation with biological dataElena Dreassi, Alessandra Tania Zizzari, Federico Falchi, et al.
Life (Basel, Switzerland)|October 27, 2022
Autophagy Inhibition Enhances Anti-Glioblastoma Effects of Pyrazolo[3,4-<i>d</i>]pyrimidine Tyrosine Kinase InhibitorsSofija Jovanović Stojanov, Ana Kostić, Mila Ljujić, et al.
Expert Opinion on Therapeutic Patents|July 15, 2017
Pyrrolo[2,3-d]pyrimidines active as Btk inhibitorsFrancesca Musumeci, Monica Sanna, Chiara Greco, et al.
Chemmedchem|November 29, 2008
C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell linesMaria Alessandra Santucci, Valentina Corradi, Manuela Mancini, et al.
International Journal of Molecular Sciences|July 29, 2025
Alzheimer's Disease Etiology Hypotheses and Therapeutic Strategies: A PerspectiveNaomi Scarano, Francesca Musumeci, Beatrice Casini, et al.
Bioorganic & Medicinal Chemistry Letters|January 31, 2009
Indolyl-pyrrolone as a new scaffold for Pim1 inhibitorsStefania Olla, Fabrizio Manetti, Emmanuele Crespan, et al.
Pageof 18

Showing results (31-40 of 173) with videos related to

Sort By:
Pageof 18
Pharmaceuticals (Basel, Switzerland)|May 25, 2024
Recent Advances in the Discovery of SIRT1/2 Inhibitors via Computational Methods: A PerspectiveNaomi Scarano, Chiara Brullo, Francesca Musumeci, et al.
Plos One|December 15, 2010
Molecular characterization of c-Abl/c-Src kinase inhibitors targeted against murine tumour progenitor cells that express stem cell markersThomas Kruewel, Silvia Schenone, Marco Radi, et al.
Bioorganic & Medicinal Chemistry|November 3, 2005
Affinity prediction on A1 adenosine receptor agonists: the chemometric approachPaola Fossa, Luisa Mosti, Francesco Bondavalli, et al.
European Journal of Medicinal Chemistry|May 20, 2025
Approaching Gallium-68 radiopharmaceuticals for tumor diagnosis: a Medicinal Chemist's perspectiveFrancesca Musumeci, Alessandro Fasce, Marta Falesiedi, et al.
European Journal of Medicinal Chemistry|May 5, 2009
Determination of permeability and lipophilicity of pyrazolo-pyrimidine tyrosine kinase inhibitors and correlation with biological dataElena Dreassi, Alessandra Tania Zizzari, Federico Falchi, et al.
Life (Basel, Switzerland)|October 27, 2022
Autophagy Inhibition Enhances Anti-Glioblastoma Effects of Pyrazolo[3,4-<i>d</i>]pyrimidine Tyrosine Kinase InhibitorsSofija Jovanović Stojanov, Ana Kostić, Mila Ljujić, et al.
Expert Opinion on Therapeutic Patents|July 15, 2017
Pyrrolo[2,3-d]pyrimidines active as Btk inhibitorsFrancesca Musumeci, Monica Sanna, Chiara Greco, et al.
Chemmedchem|November 29, 2008
C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell linesMaria Alessandra Santucci, Valentina Corradi, Manuela Mancini, et al.
International Journal of Molecular Sciences|July 29, 2025
Alzheimer's Disease Etiology Hypotheses and Therapeutic Strategies: A PerspectiveNaomi Scarano, Francesca Musumeci, Beatrice Casini, et al.
Bioorganic & Medicinal Chemistry Letters|January 31, 2009
Indolyl-pyrrolone as a new scaffold for Pim1 inhibitorsStefania Olla, Fabrizio Manetti, Emmanuele Crespan, et al.
Pageof 18